CIM
BMY icon

Cambria Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Cambria Investment Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$471K Buy
+7,764
New +$453K 0.03% 437
2015
Q3 		– Sell
-148
Closed -$10K – 317
2015
Q2 		$10K Buy
+148
New +$9.75K ﹤0.01% 250

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cambria Investment Management's BMY Position: Q1 2026 in Review

Cambria Investment Management opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 7,764 shares worth $471K. The stake represents 0.03% of the portfolio and ranks #437 among its holdings. This is a return to the name: Cambria Investment Management previously reported a position in BMY as recently as Q2 2015.

Cambria Investment Management first reported a position in BMY in Q2 2015 and has held it in 2 quarters since. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Cambria Investment Management held 7,764 shares of Bristol-Myers Squibb worth $471K as of Q1 2026.
  • Bristol-Myers Squibb was a new Cambria Investment Management position in Q1 2026.
  • Bristol-Myers Squibb made up 0.03% of Cambria Investment Management's portfolio in Q1 2026, its #437 holding.
  • Cambria Investment Management first reported a position in Bristol-Myers Squibb in Q2 2015 and has held it in 2 quarters since.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Cambria Investment Management's 13F filing for Q1 2026, filed 15 May 2026.